ECT2低表达通过转录偶联核仁DNA损伤修复导致放射治疗抵抗
研究探讨ECT2低表达导致放疗抵抗的机制,发现ECT2在ATM依赖的RNA聚合酶I作用下被招募至rDNA损伤位点,与PARP1相互作用并促其从核仁rDNA解离。ECT2缺失导致PARP1持续激活,抑制核仁转录,降低rDNA损伤暴露频率,从而介导放疗抵抗;PARP抑制剂联合照射可增敏低ECT2表达的放疗抵抗肿瘤。
要点
- ECT2表达与肺癌和鼻咽癌的放疗敏感性相关。
- ECT2低表达通过保护核仁rDNA免受持续照射损伤导致放疗抵抗。
- PARP抑制剂联合照射可增敏低ECT2表达的放疗抵抗肿瘤。
核心结论
- ECT2低表达通过转录偶联核仁DNA损伤修复导致放疗抵抗,PARP抑制剂联合照射可增敏低ECT2表达的肿瘤。
研究设计与样本
- 采用实时聚合酶链反应和蛋白质印迹确认ECT2在照射抵抗与敏感细胞系中的差异表达,用激光微照射检测rDNA损伤反应,用生物素鉴定、体内外结合实验和斑点印迹确认ECT2与PARP1的相互作用,用异种移植小鼠模型和细胞存活实验评估联合或不联合PARP1抑制剂的照射敏感性。
主要发现
- ECT2表达与肺癌和鼻咽癌的放疗敏感性相关。
- ECT2低表达主要通过阻止转录恢复来保护核仁rDNA免受持续照射暴露,从而导致放疗抵抗。
- ECT2以ATM依赖的RNA聚合酶I方式被招募至rDNA损伤位点,招募的ECT2与PARP1相互作用并促进PARP1从核仁rDNA解离。
- ECT2缺陷导致PARP1持续激活,进而抑制核仁转录,在DNA损伤下导致rDNA暴露频率降低。
临床怎么用
- 作者认为PARP抑制剂联合照射可增敏低ECT2表达的放疗抵抗肿瘤,为PARP抑制剂的应用提供了潜在视角。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radioresistance contributes to poor clinical therapeutic efficacy in most cancers. Emerging evidence shows that aberrant DNA damage repair is involved in radioresistance. This study aimed to elucidate the mechanism for radioresistance and explore the precise treatment to sensitize the radioresistant tumors. METHODS AND MATERIALS: Real-time polymerase chain reaction and Western blot were used to confirm the differential expression of epithelial cell transforming 2 (ECT2) in irradiation-resistant and sensitive cell lines. Laser microirradiation was used to examine the ribosome DNA (rDNA) damage response of ECT2. Biotin-identification, in vivo, in vitro binding assay, and dot blotting were used to confirm the interaction of ECT2 and PARP1. The xenograft mouse model and cell survival assay were used to assess the irradiation sensitivity with or without PARP1 inhibitor. RESULTS: We found the expression of ECT2 correlates with sensitivity to radiation therapy in both lung cancer and nasopharyngeal carcinoma. We demonstrated that low expression of ECT2 causes radioresistance, mainly by protecting rDNA in nucleoli from persistent irradiation exposure through transcriptional recovery prevention. ECT2 is recruited to the rDNA damage site in an ataxia-telangiectasia-mutated RNA polymerase I dependent manner. The recruited ECT2 interacts with PARP1 and facilitates the disassociation of PARP1 from rDNA in nucleoli. Thus, ECT2 deficiency results in sustained activation of PARP1, which subsequently inhibits nucleolar transcription and results in a low frequency of rDNA exposure under DNA damage. PARP inhibition synergized with irradiation can sensitize radioresistant tumors with low ECT2 expression. CONCLUSIONS: Our study provides a potential perspective for the application of PARP inhibitor to sensitize low-ECT2 expressing tumors to radiation therapy.
引用
- Qiu Y, Hu W, Wen M, et al. Low Expression of ECT2 Confers Radiation Therapy Resistance Through Transcription Coupled Nucleolar DNA Damage Repair. Int J Radiat Oncol Biol Phys. 2021. PMID: 34936928. doi:10.1016/j.ijrobp.2021.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。